Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.33321/cdi.2022.46.67 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
J Infect
December 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute of Australia, Nedlands, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; General
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.
Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.
EBioMedicine
December 2024
The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia. Electronic address:
Article Synopsis
- Ongoing research is essential for tracking and understanding the emergence of new SARS-CoV-2 variants, particularly as diagnostic testing declines in Australia during the COVID-19 pandemic.
- In 2023, collaborations with pathology and genomics teams allowed for the monitoring of SARS-CoV-2 variants in New South Wales through various methods, including viral culture and analysis of immune responses from a large pool of blood donations.
- Findings indicated that while existing antibodies generally neutralized many variants, specific mutations in emerging strains, particularly JN.1, suggested future challenges in controlling their spread due to enhanced transmissibility.
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol.
Trials
November 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia.
Article Synopsis
- COVID-19 vaccination in Australia began in February 2021, with initial vaccines requiring two doses; booster vaccinations are now being recommended to maintain immunity.
- The PICOBOO trial is a multi-site study that tests various COVID-19 booster vaccines in children and adults, looking at their effectiveness and safety across different vaccination histories and age groups.
- This adaptive trial structure allows for rapid adjustments to research elements, helping to explore the best approaches for combating COVID-19 variants and assessing new vaccines as they are introduced.
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
J Infect
December 2024
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia; School of Medicine, University of Western Australia, Crawley, Australia; Centre for Child Health Research, University of Western Australia, Crawley, Australia; General Paediatrics and Immunology Depa
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Methods: Immunocompetent adults who received any first booster ≥three months prior were eligible.
ATAGI targeted review 2023: Vaccination for preventing influenza in Australia.
Commun Dis Intell (2018)
July 2024
Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia.
Article Synopsis
- Annual influenza epidemics significantly impact global health and economy, but their activity dropped during the COVID-19 pandemic, only to resurge in Australia in early 2022, coinciding with the Omicron variant wave.
- * The current influenza vaccination program in Australia recommends yearly vaccinations for all individuals aged 6 months and older, with free vaccines provided for at-risk groups, but overall coverage, particularly among younger populations, remains low.
- * To improve vaccination rates, strategies such as better monitoring, culturally appropriate resources, and addressing specific population needs are essential for enhancing the overall effectiveness of the immunization program.